Fenofibrate Capsule
Product Images NDC 13668-440

This text describes the Fredrickson Classification of Hyperlipoproteinemias, which categorizes different types of lipoprotein elevations based on major and minor factors. The NCEP Treatment Guidelines are also discussed, which provide initiation and goal levels for LDL-cholesterol mg/dL based on definite risk factors for atherosclerotic disease. The text also mentions risk factors for coronary heart disease and notes that physicians should exercise clinical judgment for patients with LDL-C levels between 100 and 120 mg/dL.*

This is a list of adverse reactions reported during a clinical trial with Fenofibrate and a Placebo. The reactions are classified by body systems affected. The listed reactions include abdominal pain, back pain, headache, abnormal liver function tests, nausea, constipation, increased ALT, increased CPK, increased AST, respiratory disorder, and rhinitis. The dosage used in the trial is equivalent to 145mg of Fenofibrate. The statement "#*Significantly different from Placebo" suggests that the reactions are more likely to occur with Fenofibrate than with Placebo.*

This is a medication called Fenofibrate, presented in capsules of 67 mg (micronized). It is recommended not to accept the medication if the seal over the bottle opening is broken or missing. It should be stored between 20°C to 25°C (68°F to 77°F) and protected from moisture. It is important to keep all medications out of the reach of children. Adult dosage should be determined by a medical professional according to the prescribing information. The medication is manufactured by Torrent Pharmaceuticals Ltd. in India and distributed by Torrent Pharma Inc. in Levittown, PA 19057.*

Fenofibrate Capsules, USP are a medication containing 134mg of micronized Fenofibrate, USP. They should be stored at a temperature between 20°C and 25°C and protected from moisture. The capsules must be kept out of reach of children and dispensed in a tight, light-resistant container with a child-resistant closure. The appropriate dosage information is available in the accompanying prescribing information. If the seal over the bottle opening is broken or missing, do not accept it. It is manufactured by Torrent Pharmaceuticals Ltd., Bharuch-392130, INDIA, and manufactured for Torrent Pharma Inc., Levittown, PA 19057. The product is available in a 90-capsule pack.*

This is a medication named Fenofibrate, USP, available in a capsule form containing 200mg of the drug. It is required to be stored at temperatures ranging between 20°-25°C and should be protected from moisture. The medicine should be dispensed with a tight light-resistant container and needs to have a child-resistant closure. The manufacturer is B ML B under license number 672572010, and it is manufactured for Torrent Pharma Inc. in Levittown, PA 19057. The label mentions some dosage information along with a warning to keep this medication away from the reach of children. The NDC code of the product is 13668-438-90.*